<DOC>
	<DOCNO>NCT00961779</DOCNO>
	<brief_summary>The purpose study obtain evidence safety NNZ-2566 healthy female volunteer determine pharmacokinetics ( PK ) NNZ-2566 healthy female volunteer .</brief_summary>
	<brief_title>Safety Study NNZ-2566 Healthy Female Subjects</brief_title>
	<detailed_description>To obtain evidence safety NNZ-2566 healthy female volunteer , compare placebo administer 10 minute intravenous ( i.v . ) bolus infusion , administer 10-minute bolus infusion immediately follow continuous 72-hour maintenance infusion . To determine blood pharmacokinetics ( PK ) intravenous dose NNZ-2566 healthy female volunteer administer 10-minute bolus infusion , administer 10-minute bolus follow continuous 72-hour maintenance infusion .</detailed_description>
	<mesh_term>Brain Injuries</mesh_term>
	<criteria>Aged 18 year 50 year ( inclusive ) . Females . Weight 50 105 kg BMI 18 30 kg/m2 . General Health : Healthy , determine medical history particular attention : drug history identify know drug allergy presence drug abuse ; chronic use medication ; thorough review body system . This also determine clinically significant abnormal finding physical examination , include electrocardiogram ( ECG ) , opinion Investigator would jeopardize safety subject impact validity study result . Venous Access : Volunteers adequate venous access leave right arm allow collection blood sample drug administration . Language : Fluent English language . Informed Consent : Have voluntarily give write informed consent participate study . Pregnant lactate female exclude participate study . History allergy and/or hypersensitivity state ingredient formulation . History clinically significant gastrointestinal , hepatic , renal , cardiovascular , dermatological , immunological , respiratory , endocrine , oncological , neurological , metabolic , psychiatric disease hematological disorder . Any history asthma last 10 year . A creatinine clearance le 75 mL/min . Any predisposing condition might interfere absorption , distribution , metabolism , and/or excretion investigational product . History abnormal bleeding tendency thrombophlebitis unrelated venepuncture intravenous cannulation . History Hepatitis B , positive test Hepatitis B surface antigen , history Hepatitis C , positive test Hepatitis C antibody , history HIV infection demonstration HIV antibody . Pregnancy . Any evidence organ dysfunction , clinically significant clinical laboratory value , include liver function test ( LFT ) &gt; 1.5 x upper limit normal ( ULN ) . Difficulty abstain alcohol 48 hour prior dose administration completion blood sample exit assessment . History , current evidence , abuse alcohol drug substance , licit illicit , positive urine drug screen drug abuse . Difficulty abstain prescription medication 14 day prior dose administration duration study . Difficulty abstain overthecounter ( OTC ) medication herbal supplement 14 day prior dose administration duration study , ( exception occasional analgesia , vitamin nutrient supplement use , discretion Investigator ) . Difficulty abstain food and/or beverage contain caffeine xanthine , ( e.g. , coffee , tea , cola chocolate ) 24 hour prior dose administration whilst confine clinical study facility . History psychiatric illness may impair ability provide write informed consent . Poor protocol compliers unlikely attend . Receipt drug part research study within 30 day initial dose administration study . Standard blood donation ( usually 550 mL ) within 12week period dose administration . Unusual dietary habit excessive unusual vitamin intake . Vaccination immunization within 30 day initial dose administration . QT/QTc Exclusions i.e. , mark baseline prolongation correct QT interval &gt; 450 m two ECGs , history risk factor Torsade de Pointes ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>